Megakaryon

1 known investors

Megakaryon is a Japanese regenerative-medicine venture developing platelet products derived from human iPS cells, including HLA-homozygous iPS-cell-derived platelets (MEG-002) that have advanced into clinical trials. It became a subsidiary of Sysmex Corporation in 2023.

BiotechLongevityMedical Devices